Previous 10 | Next 10 |
IRVINE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmu...
After a long holiday weekend, the markets were off to a slow start on Tuesday. Shares of penny stocks and stocks over $5 went back into volatility mode. Meanwhile, significant indexes slipped below Friday’s closing levels. The S&P 500 ( NYSEARCA: SPY ) dipped back to the ...
Eledon Pharmaceuticals (NASDAQ:ELDN) stock rose ~9% premarket May 31 after the company said tegoprubart met the main goals of safety and tolerability in a phase 2a trial of tegoprubart (formerly AT-1501) in patients with amyotrophic lateral sclerosis (ALS). ALS is progressive nervou...
Tegoprubart was well-tolerated, with no drug-related serious adverse events Dose dependent target engagement was demonstrated, and ALS associated pro-inflammatory biomarkers were both observed and significantly reduced in a dose dependent manner Target engagement and lev...
If you’re shopping for a wallet and one comes complete with $100 worth of cash inside, and is priced at $60, would you think there is value to this purchase? A situation similar to this has evolved in many biotech stocks. Their balance sheet cash and cash equivalents exceed their market...
Eledon Pharmaceuticals, Inc. (ELDN) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Paul Little – Chief Financial Officer David-Alexandre Gros – Chief Executive Officer Steve Perrin – President and Chief Scientific Officer Jeff Bornstein ...
Eledon Pharmaceuticals press release (NASDAQ:ELDN): Q1 GAAP EPS of -$0.69. The company had approximately $76.7M in cash and cash equivalents as of Mar. 31. For further details see: Eledon Pharmaceuticals GAAP EPS of -$0.69
Topline data for Phase 2a tegoprubart study in amyotrophic lateral sclerosis (ALS) anticipated in June 2022 First patient dosed in Phase 2a trial evaluating tegoprubart in IgA Nephropathy with initial readout expected in late 2022 Successfully completed non-human primate...
Eledon Pharmaceuticals (NASDAQ:ELDN) said the first patient was dosed in a phase 2a trial of tegoprubart to treat patients with IgA Nephropathy (IgAN). IgAN is a type of kidney disease which occurs when an antibody called immunoglobulin A builds up in the kidneys. The study will enroll u...
IRVINE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, ...
News, Short Squeeze, Breakout and More Instantly...
Eledon Pharmaceuticals Inc Com Company Name:
ELDN Stock Symbol:
NASDAQ Market:
Eledon Pharmaceuticals Inc Com Website:
IRVINE, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company’s management team will be hosting one-on-one meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism, on July 9, ...
Data from 13 participants presented at the American Transplant Congress continue to support safety and tolerability profile of tegoprubart Overall mean eGFR of all reported time points after day 30 post-transplant of 70.5 mL/min/1.73m² Mean eGFR measured above 60 mL/min/1.73m...